Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction

KATSUMASA NAGANO¹,², JUNJI ISHIDA¹,², MADOKA UNNO¹,², TANOMU MATSUKURA¹,² and AKIYOSHI FUKAMIZU¹,²

¹Life Science Center, Tsukuba Advanced Research Alliance; ²Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba 305-8577, Japan

Received November 1, 2012; Accepted February 13, 2013

DOI: 10.3892/mmr.2013.1378

Abstract. Apelin is the endogenous ligand of APJ, which belongs to the family of G protein-coupled receptors. Apelin and APJ are highly expressed in various cardiovascular tissues, including the heart, kidney and vascular endothelial and smooth muscle cells. Although apelin exerts hypotensive effects via activation of endothelial nitric oxide synthase (eNOS), the ability of apelin to regulate blood pressure under pathological conditions is poorly understood. In the current study, N⁵-nitro-L-arginine methyl ester (L-NAME), a potent NOS inhibitor, was administered chronically, to induce peripheral vascular damage in mice. L-NAME-treated mice exhibited hypertension, increased vascular cell adhesion molecule-1 and plasminogen activator inhibitor-1 mRNA levels in the aorta and impaired vasodilatation, consistent with endothelial damage. Three days following withdrawal of L-NAME treatment, the blood pressure response to apelin stimulation was assessed. Although apelin reduced blood pressure in non-treated mice, it was found to transiently elevate blood pressure in L-NAME-treated mice. These results indicate that apelin functions as a vasopressor peptide under pathological conditions, including vascular endothelial dysfunction in mice.

Introduction

Apelin was originally identified in bovine stomach as the endogenous peptide ligand of the APJ receptor, which belongs to the G protein-coupled receptor family (1). Apelin and APJ are expressed in various cardiovascular tissues, including the heart, kidney and vascular endothelial and smooth muscle cells (2). Apelin has been shown to induce hypotensive effects via the activation of endothelial nitric oxide synthase (NOS) in vascular tissues (3). In addition, we previously revealed that APJ is involved in apelin-dependent hypotensive activity and the activation of endothelial NOS (eNOS) using APJ-deficient mice (4). Therefore, it has been hypothesized that apelin functions as a vasodilator under steady state conditions.

By contrast, it has also been reported that apelin contracts saphenous veins from which the endothelium has been physically removed ex vivo (5) and phosphorylates myosin light chain, the rate-limiting event for vascular constriction, in cultured vascular smooth muscle cells (6). Although apelin has been suggested to function as a vasopressor, there is no evidence indicating whether its vasoconstrictive properties are effective during blood pressure homeostasis.

In the current study, the apelin-dependent effects on blood pressure were analyzed during vascular endothelial dysfunction, the most common predisposing factor in various cardiovascular diseases, including hypertension, thrombus, stroke, renal failure and cardiac failure (7,8). To induce vascular endothelial damage in mice, N⁵-nitro-L-arginine methyl ester (L-NAME), a potent NOS inhibitor, was chronically administered (9-11). L-NAME-treated mice exhibited hypertension, increased expression of endothelial dysfunction-related genes and impaired vasodilatation. Under these conditions, apelin was revealed to transiently elevate blood pressure in L-NAME-treated mice, although a hypotensive effect was observed in non-treated mice. These results indicate that apelin has a pathophysiological role in mice with endothelial dysfunction.

Materials and methods

Generation of hypertensive conditions in mice. Animal experiments were performed using 2-month-old male ICR mice under conscious and unrestrained conditions. L-NAME (Sigma-Aldrich, St. Louis, MO, USA) was administered as previously described (12). Briefly, L-NAME was suspended in water (1 mg/ml) and the mice were allowed to drink freely for 1 month. The L-NAME-containing water was replaced every week. Following L-NAME treatment, the bottle was changed to normal water for 3 days to allow the L-NAME to be excreted from the mice. Age- and gender-matched control mice were used in all experiments. Animal experiments were
approved by the Institutional Animal Experiment Committee of the University of Tsukuba. Experiments were performed in accordance with the Regulation of Animal Experiments of the University of Tsukuba and the Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Aorta preparation and total RNA extraction. Aortas were excised from mice, the perivascular limbs were removed and the aortas were frozen rapidly in liquid nitrogen. Total RNA was isolated from the aortas using an RNAsys Total RNA Isolation System kit (Promega Corporation, Madison, WI, USA). Briefly, frozen aortas were ground to a powder using the Multi-Beads Shocker (Yasui Kikai Corporation, Osaka, Japan) suspended in denaturing solution and mixed thoroughly with phenol chloroform. The mixture was centrifuged (14,000 rpm at 4°C for 20 min) to collect the supernatant, following which Ethachinmate (Nippon Gene Co., Ltd., Tokyo, Japan) was added. Finally, total RNA was collected using the ethanol precipitation method.

Gene expression analysis by real-time RT-PCR. Total RNA (~1 µg) was reverse-transcribed using a Quantitect Reverse Transcription kit (Qiagen, Hilden, Germany) and then real-time PCR was performed using a Thermal Cycler Dice and SYBR Premix ExTaq II. Relative gene expression was determined by the ∆∆Ct method. The following primers were used for amplification: GAPDH, 5'-TGT GTC CGT CGT GGA TCT GA-3' and 5'-GTT GCA-3'; L-NAME-treated mice. Each parameter was measured at 0, 5, 10, 15 and 30 days following the start of treatment. Data represent the mean ± SEM. Each group, n=5-8. *P<0.05 and **P<0.01, vs. control. L-NAME, NG-nitro-L-arginine methyl ester.

Blood pressure measurements and intraperitoneal injection of apelin. Systolic blood pressure was measured using a programmable sphygmomanometer (BP-200; Softron Co. Ltd., Tokyo, Japan) using the tail cuff method as previously described (13). Prior to measurement, a 2-day preliminary examination was performed and the mice were familiarized with the sphygmomanometer. Unanesthetized mice were introduced into a holder mounted on a thermostatically controlled warming plate and maintained at 37°C throughout the measurement. Apelin was intraperitoneally injected while the mice were conscious and unrestrained. [Pyr]-apelin-13 (Peptide Institute, Inc., Osaka, Japan) was suspended in saline (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). Following measurement of basal systolic blood pressure, [Pyr]-apelin-13 was intraperitoneally injected at 296 µg/kg body weight. Systolic blood pressure was measured continuously for ~5 min and data were collected every 20 sec.

Measurement of isometric tension. Mice were anesthetized with isoflurane and thoracic aorta rings were excised in ice-cold Krebs-Henseleit buffer (NaCl, 118; KCl, 4.7; CaCl₂, 1.8; NaH₂PO₄, 1.8; MgSO₄, 1.2; NaHCO₃, 25; and glucose, 11.1). The rings were cut into 3-mm sections and mounted in Easy Magnus system (Kishimoto Medical Instruments, Kyoto, Japan). The mounted rings were allowed to equilibrate for 60 min under passive tension of 35 mN in Krebs-Henseleit buffer gassed with 95% O₂/5% CO₂ at 37°C. During the following hour, the resting tension was increased twice to 60 mM KCl and once to 80 mM to optimize constriction. The rings were pre-contracted with noradrenaline (L-(−)-norepinephrine-(-)-bitartrate; Calbiochem, La Jolla, CA, USA) to achieve 20-30% of the maximal tone. Vasodilation was measured at increasing concentrations of acetylcholine (Ach; Sigma-Aldrich). Following the addition of each concentration of Ach, the subsequent dose was not added until the baseline had restabilized.

Results

Hypertension in L-NAME-treated mice. L-NAME-induced hypertension in mice has been demonstrated to increase peripheral organ damage, including vascular endothelial dysfunction (14). To evaluate apelin-dependent blood pressure regulation during endothelial injury, vascular damage was induced in mice by L-NAME treatment. After administering L-NAME in the drinking water for 1 month, the body weight and blood pressure of non-treated and L-NAME-treated mice were measured. The body weight of the L-NAME-treated mice did not differ from that of the non-treated control mice (Fig. 1A). By contrast, the blood pressure of the L-NAME-treated mice was significantly higher than that of the control mice (Fig. 1B). The difference in blood pressure between the two groups was statistically significant (P<0.05).
pressure of the L-NAME-treated group was found to significantly increase by ~20-30 mmHg (Fig. 1B, closed circles).

Expression levels of vascular endothelial damage-related genes during L-NAME treatment. To examine the effects of L-NAME on vascular injury, the expression levels of various endothelial damage markers were assessed, including VCAM-1 (15) and the fibrinolytic system regulation factor, PAI-1 (16,17). As demonstrated in Fig. 2, VCAM-1 and PAI-1 mRNA levels were found to be significantly increased in aortas obtained from the L-NAME-treated group, compared with those of the control (Fig. 2A and B). In addition, the gene expression levels of Tie2 and eNOS, a marker of vascular endothelial cells and an important vasodilative factor, respectively, were determined. Although Tie2 gene expression in L-NAME-treated and control aortas did not differ, eNOS gene expression was identified to be significantly decreased in the L-NAME-treated mice compared with the controls (Fig. 2C and D).

Impaired vasodilation in L-NAME-treated aorta. Hypertension and vascular endothelial dysfunction are known to be major causes of impaired vasodilatation (15). Therefore, the acetylcholine-induced vasodilative activity of aortas obtained from L-NAME-treated mice was evaluated using an ex vivo assay. Aortic rings from the control group were completely dilated at a dose of 10^{-6} M acetylcholine (Fig. 2E, open circles). By contrast, aortic rings from which endothelial cells had been physically removed reacted minimally to acetylcholine (Fig. 2E, closed circles). For L-NAME-treated aortic rings, acetylcholine-induced vascular dilation was observed to occur in a dose-dependent manner, however, the maximum vasodilation was not reached completely (Fig. 2E, closed squares). Figs. 1 and 2 confirmed that endothelial cells remained structurally intact but were functionally damaged, as previously described (18).

Hypertensive action of apelin in L-NAME-treated mice. To investigate the effects of apelin on blood pressure, apelin was administered to mice that were untreated or treated with L-NAME. In untreated mice, apelin administration transiently decreased blood pressure, compared with the effects of saline (Fig. 3A, filled circles). Of note, however, blood pressure was transiently elevated in the L-NAME-treated mice and the degree of increased blood pressure was significantly higher than that of saline-injected control mice (Fig. 3A, filled squares).
Finally, due to its importance in apelin-mediated hypertension, APJ expression in the aorta was examined using RT-PCR. Although the expression level of CD31, a marker of endothelial cells, was found to be significantly decreased by gently rubbing the aortic intimal surface (Fig. 3B), APJ gene expression was retained in the aorta (Fig. 3C). These results indicate that APJ is also expressed in smooth muscle cells, where it may regulate changes in apelin sensitivity following L-NAME treatment.

Discussion

It is well known that systemic apelin administration releases vasodilatory substances, including NO, and lowers blood pressure (3,4). In the present study, the importance of apelin on blood pressure regulation under pathological conditions was analyzed by chronically treating mice with L-NAME (Fig. 1), an analog molecule of asymmetric di-methyl arginine (ADMA) that induces endothelial damage, one of the most serious factors in various cardiovascular diseases (7,8). L-NAME, like ADMA, inhibits NO production by suppressing the enzymatic activity of eNOS and induces vascular endothelial dysfunction accompanied by hypertension (14). Under these conditions, L-NAME-treated mice were confirmed to have hypertension, increased expression levels of endothelial dysfunction-related genes and impaired vasodilation (Figs. 1 and 2).

Treatment with L-NAME did not affect the expression levels of the Tie2 gene, a marker of vascular endothelial cells (Fig. 2C), indicating that endothelial cells were retained by the damaged vascular walls (Fig. 2A and B). By contrast, L-NAME treatment reduced eNOS mRNA levels (Fig. 2D). It has previously been reported that eNOS gene expression levels decrease upon L-NAME administration in rat aortic tissue (18). This observation is consistent with results of the present study and the reduced NO bioavailability and accelerated pathological conditions may be involved in the impaired vasodilation (Fig. 2E) associated with endothelial damage.

Under this pathological condition, apelin administration was found to provoke a vasopressor response, whereas it lowered the blood pressure of non-treated mice (Fig. 3A). The hypertensive action of L-NAME in mice may mediate the direct vasoconstrictive effects of apelin on vascular smooth muscle, since APJ expression was detected in aortic mouse tissues from which endothelial cells had been removed (Fig. 3B and C). Previously, it was reported that apelin passes through the ADMA-damaged endothelial barrier due to its increased permeability, as assessed by an in vitro assay (19). It is possible that apelin gains access to vascular smooth muscle cells during endothelial damage and constricts these cells.

In conclusion, the results of the present study indicate that apelin treatment in mice affects blood pressure in cases where blood pressure that is relatively low under normal conditions becomes elevated under the pathological conditions that are induced by endothelial dysfunction in vivo. Therefore, it is hypothesized that protection from endothelial damage is not only required to produce NO, but also to prevent the action of biological substances that constrict vessels. In this respect, the results of the current study provide a more detailed insight and an improved understanding of the complexities of blood pressure regulation by apelin.

Acknowledgements

The authors thank members of the Fukamizu Laboratory for their helpful discussions and encouragement. The study was supported by Grants-in-Aid for Scientific Research (B), Grants-in-Aid for Young Scientists (B), Grants-in-Aid for JSPS Fellows from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Grants-in-Aid for Research Fellow of the Japan Society for the Promotion of Science.

References

1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H and Fujino M: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476, 1998.
2. Kleinz MJ, Skepper JN and Davenport AP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 126: 233-240, 2005.
3. Cheng X, Cheng XS and Pang CC: Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 470: 171-175, 2003.
4. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iuchi T, Harada S, Sugaya T, Matsuura H, Yamamoto R, Shiotai N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N and Fukamizu A: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279: 26274-26279, 2004.
5. Katagampola SD, Maguire J, Matthewson SR and Davenport AP: [125I]-(Pyr)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132: 1255-1260, 2001.
6. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, Fukamizu A, Kitamura H and Umemura S: Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 26: 1267-1272, 2006.
7. Cohen JN: Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl 17: 41-44, 1999.
8. Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22 (Suppl 4): S1-S14, 1993.
9. Baylis C, Mitruba B and Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
10. Bartunek J, Weinberg EO, Tajima M, Roehrback S, Katz SE, Douglas PS and Lorell BH: Chronic NG-nitro-L-arginine methyl ester-induced hypertension novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101: 423-429, 2000.
11. Dornas WC and Silva ME: Animal models for the study of arterial hypertension. J Biocios 36: 731-737, 2011.
12. Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiiuchi M, Tasaki H, Huang PL, Sasaki Y, Yanagihara N and Nakashima Y: Long-term treatment with No-nitro-l-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient. Circulation 106: 1729-1735, 2002.
13. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K and Murakami K: Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268: 11617-11621, 1993.
14. Hobbs AJ and Gibson AL: L-N^ω-nitro-arginine and its methyl ester are potent inhibitors of non-adrenergic, non-cholinergic transmission in the rat anococcygeus. Br J Pharmacol 100: 749-752, 1990.
15. Widlansky ME, Gokce N, Keaney JF Jr and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003.

16. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL and Eriksson P: Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 59: 169-180, 2003.

17. Nürnberger W, Michelmann I, Burdach S and Göbel U: Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol '76: 61-65, 1998.

18. De Gennaro Colonna V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F and Muller E: Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 450: 61-66, 2002.

19. Wang LY, Zhang DL, Zheng JF, Zhang Y, Zhang QD and Liu WH: Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32: 2436-2443, 2011.